{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
US Previously Marketed
First approved in 1955
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Pentoxyverine is a non-opioid antitussive used to prevent cough caused by common cold. It is used as an active ingredient of several oral over-the-counter cough suppressants alone or in combination with other medications, especially decongestants. Certuss is a combination of pentoxyverine and guaifenesin. Pentoxyverine is FDA pregnancy category C drug. Known as anticonvulsant, and spasmolytic agent.
Status:
US Previously Marketed
Source:
ARLIDIN NYLIDRIN HYDROCHLORIDE by USV
(1961)
Source URL:
First approved in 1955
Class (Stereo):
CHEMICAL (MIXED)
Targets:
Nylidrin (Buphenine, Arlidin) is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor. In peripheral vascular disorders, Arlidin (nylidrin HCl) increases walking ability and promotes healing of trophic ulcers. Nylidrin hydrochloride acts predominantly by beta-receptor stimulation. Beta stimulation with nylidrin has been demonstrated in a variety of isolated tissues from rabbits, guinea pigs and dogs. It has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat and in unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of actions is a greater blood supply to ischemic tissues, with usually minimal change in blood pressure. Arlidin may be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders. Short-term (3 months’ duration) and long-term (12 months’ duration) clinical studies have demonstrated a modest improvement in ability to perform general activities of daily living, self-care and in a capability for social interactions. The mechanism whereby nylidrin may provide relief of selected symptoms in some elderly patients with organic brain disorders is not known.
Status:
US Previously Marketed
Source:
TERGEMIST SODIUM ETHASULFATE by ABBOTT
(1955)
Source URL:
First approved in 1955
Source:
TERGEMIST SODIUM ETHASULFATE by ABBOTT
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Sodium ethasulfate is a clear, colorless, viscous, and nonflammable liquid that belongs to the sodium sulfate chemical group. Sodium ethasulfate is usually stable; however, it is incompatible with strong oxidizing agents. Due to its unique solubility and penetrating action, it is widely used in various end-user industries such as textile, chemical production, pharmaceuticals, agrochemicals, metal working, and food processing. Sodium ethasulfate is used as wetting agent in the textile industry. The product is used along with calcium hypochlorite as a bleaching agent. The product is used as mercerizing agent for cotton processing in the chemical industry. Sodium ethasulfate is employed as intermediate in anoinic surfactants that are used for dishwashing detergents. It is also used as surfactant in lye washing and peeling process. In the pharmaceutical industry, it is used to enhance the bactericidal properties of generic antiseptics that are more acidic. It is also employed as surfactant in penicillin production for breaking undesired reaction conditions.
Status:
US Previously Marketed
First approved in 1954
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Piperidolate hydrochloride is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs. It’s usually used to kill the cramp-like pain of gastric/duodenal ulcer, gastritis, enteritis, gallstones, cholecystitis and biliary tract dyskinesia and to improve some symptoms in threatened miscarriage/premature delivery. Piperidolate blocked the contraction of ACh, Ba ++ and electrical stimulations on the isolated rat, mouse and guinea-pig ileum and trachea. In guinea-pig teania caeci, piperidolate like papaverine blocked specifically the tonic response, however, piperidolate in high doses completely blocked both spike and tonic responses. These results indicate that spasmolytic action of piperidolate like that of papaverine may depend upon inhibition of the release of store Ca++. Moreover piperidolate, given at high doses, may inhibit the contractile elements in the smooth muscle. In the rat uterus pretreated with sex hormones, piperidolate nonspecifically blocked the contraction of ACh, Ba ++ and oxytocin and sex hormones had no influence on the spasmolytic action of piperidolate.
Status:
US Previously Marketed
Source:
PROPANTHELINE BROMIDE by WATSON LABS
(1975)
Source URL:
First approved in 1953
Source:
PRO-BANTHINE by SHIRE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Propantheline is an antimuscarinic agent used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut) or bladder, and involuntary urination (enuresis). It can also be used to control the symptoms of irritable bowel syndrome and similar conditions. Propantheline is one of a group of antispasmodic medications which work by blocking the action of the chemical messenger acetylcholine, which is produced by nerve cells, to muscarinic receptors present in various smooth muscular tissues, in places such as the gut, bladder, and eye. Normally, the binding of acetylcholine induces involuntary smooth muscular contractions. Varying degrees of drying of salivary secretions may occur as well as decreased sweating. Ophthalmic side effects include blurred vision, mydriasis, cycloplegia, and increased ocular tension. Other reported adverse reactions include urinary hesitancy and retention, tachycardia, palpitations, loss of the sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, nausea, vomiting, constipation, bloated feeling, impotence, suppression of lactation, and allergic reactions or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.
Status:
US Previously Marketed
Source:
RAVOCAINE AND NOVOCAIN W/ LEVOPHED by EASTMAN KODAK
(1952)
Source URL:
First approved in 1952
Source:
RAVOCAINE AND NOVOCAIN W/ LEVOPHED by EASTMAN KODAK
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Propoxycaine hydrochloride is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride. Propoxycaine Hydrochloride is the hydrochloride salt form of propoxycaine, a para-aminobenzoic acid ester. Propoxycaine binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. This results in a loss of sensation.
Status:
US Previously Marketed
First approved in 1952
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
DIBUTOLINE, an antispasmodic drug, produces paresis of smooth muscles innervated by the parasympathetic nervous system. Its effect on the smooth muscles, therefore, simulates that of paralysis of the oculomotor nerve, that is, paresis of the sphincter of the iris and the ciliary muscles. DIBUTOLINE has no effect on the ocular muscles innervated by the sympathetic nervous system.
Status:
US Previously Marketed
Source:
TELEPAQUE by GE HEALTHCARE
(1951)
Source URL:
First approved in 1951
Source:
TELEPAQUE by GE HEALTHCARE
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Iopanoic acid is a representative iodinated ionic monomeric contrast medium.
Status:
US Previously Marketed
Source:
ENLON-PLUS by NORVIUM BIOSCIENCE
(1991)
Source URL:
First approved in 1951
Source:
TENSILON by PAI HOLDINGS PHARM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
Status:
US Previously Marketed
Source:
ENLON-PLUS by NORVIUM BIOSCIENCE
(1991)
Source URL:
First approved in 1951
Source:
TENSILON by PAI HOLDINGS PHARM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
